Immune Pharmaceuticals Enters a Research Partnership to Develop Mono and Bispecific Antibodies Against Novel Targets in the Tumor Microenvironment

NEW YORK Jan. 23 2017 PRNewswire Immune Pharmaceuticals Inc. NASDAQ IMNP "Immune" a clinicalstage biopharmaceutical company developing novel therapeutics for the treatment of immunoinflammatory diseases and cancers announced today that it ha...